Dianthus Therapeutics, Inc. (DNTH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 85.4 |
| Open | 84.6 |
| Day High | 86.81 |
| Day Low | 84.52 |
| 52-Week High | 117.88 |
| 52-Week Low | 32.22 |
| Volume | 129,318.49 |
| Average Volume | 824,215 |
| Market Cap | 4.84B |
| PE | -20.85 |
| EPS | -4.15 |
| Moving Average 50 Days | 104 |
| Moving Average 200 Days | 81.6 |
| Change | 1.15 |
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
GlobeNewswire Inc.
Mar 11, 2026 2:54 AM GMT
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the trea
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
GlobeNewswire Inc.
Mar 09, 2026 8:01 PM GMT
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the trea
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: Company will maintain the Part A dose of 300mg/2m